Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for patients with serious, rare diseases through the application of gene therapy technology. The Company currently has four programs in development: AT132 for the treatment of X-Linked Myotubular Myopathy, an ultra-rare, severe, debilitating disease that affects skeletal muscles. AT342 for the treatment of Crigler-Najjar Syndrome, a rare, congenital autosomal recessive monogenic disease characterized by severely high levels of bilirubin in the blood and risk of irreversible neurological damage and death. AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia, an inherited disease characterized by abnormal ventricular heartbeats. AT982 for the treatment of Pompe disease, a rare, inherited disorder characterized by progressive muscle weakness and respiratory impairment.